{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T22:40:48Z","timestamp":1764715248452,"version":"3.44.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>This study aimed to develop population pharmacokinetic (PK) models of cefoperazone and sulbactam through simultaneous analysis of plasma and urine data in pediatric patients and to optimize dosing regimens based on PK\/pharmacodynamic (PD) simulation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Population PK models of cefoperazone and sulbactam were separately developed by simultaneously fitting plasma and urine data from pediatric patients described in 9 published articles. Probabilities of attaining the bactericidal target of 70% of free time above minimum inhibitory concentration (70% <jats:italic toggle=\"yes\">fT<\/jats:italic> &gt; MIC) for cefoperazone against clinical isolates of common bacteria were estimated based on the final model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Seventy-eight pediatric patients were the subjects for PK modeling (0.83\u201314.6 years old and 6\u201351.6\u2009kg of body weight). A total of 439 plasma concentrations and 138 urinary excretions up to 7 hours after administration were used for population PK modeling. The data were adequately described by 2-compartment models for cefoperazone and sulbactam. Age was not a statistically significant covariate in the PK of both drugs. For empiric therapy of community-acquired pneumonia, the PK\/PD breakpoint of 0.5-hour infusion of 20\u2009mg\/kg (cefoperazone-sulbactam dose ratio of 1:1) 4 times daily was 0.13 \u03bcg\/mL and could cover MIC<jats:sub>90<\/jats:sub> of <jats:italic toggle=\"yes\">Streptococcus pneumoniae<\/jats:italic> (MIC<jats:sub>90<\/jats:sub> = 0.125 \u03bcg\/mL) and <jats:italic toggle=\"yes\">Haemophilus influenzae<\/jats:italic> (MIC<jats:sub>90<\/jats:sub> = 0.125 \u03bcg\/mL). However, since MIC<jats:sub>90<\/jats:sub> values for nosocomial pathogens are high (MIC<jats:sub>90<\/jats:sub> = 2 \u03bcg\/mL for <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic> and MIC<jats:sub>90<\/jats:sub> = 4 \u03bcg\/mL for <jats:italic toggle=\"yes\">Morganella morganii<\/jats:italic>), a 4-hour infusion of 60\u2009mg\/kg (cefoperazone-sulbactam dose ratio of 2:1) 4 times daily might be better to cover many pathogens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This study described population PK models of cefoperazone and sulbactam detailing the excretion process with urine data in pediatric patients and developed optimal dosing regimens of cefoperazone-sulbactam including extended infusion in consideration with pathogens, based on PK\/PD simulation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004832","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T17:00:41Z","timestamp":1744736441000},"page":"866-872","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Population Pharmacokinetic Analysis of Cefoperazone-Sulbactam in Pediatric Patients: Simultaneous Analysis of Plasma and Urine Data for Optimal Dosing Regimens"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1174-0787","authenticated-orcid":false,"given":"Tetsushu","family":"Onita","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Shimane University Hospital, Izumo, Shimane"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yui","family":"Sano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shimane University Hospital, Izumo, Shimane"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuro","family":"Ikawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacotherapy, Hiroshima University, Minami-ku, Hiroshima, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shimane University Hospital, Izumo, Shimane"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Tamaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shimane University Hospital, Izumo, Shimane"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shimane University Hospital, Izumo, Shimane"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"year":"2023","key":"R1-20250819"},{"key":"R4-20250819","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 3","key":"R5-20250819","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1086\/321854","article-title":"Does the dose matter?","volume":"33","author":"Craig","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R6-20250819","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1039\/D1AY01385H","article-title":"Pharmacokinetic and pharmacodynamic analysis of cefoperazone\/sulbactam for the treatment of pediatric sepsis by Monte Carlo simulation.","volume":"14","author":"Ye","year":"2022","journal-title":"Anal Methods"},{"key":"R7-20250819","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/INF.0000000000003496","article-title":"Pharmacodynamic evaluation of ampicillin-sulbactam in pediatric patients using plasma and urine data.","volume":"41","author":"Onita","year":"2022","journal-title":"Pediatr Infect Dis J"},{"key":"R8-20250819","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2024\/4684986","article-title":"Cerebrospinal pharmacokinetic analysis and pharmacodynamic evaluation of ceftriaxone in pediatric patients with bacterial meningitis.","volume":"2024","author":"Onita","year":"2024","journal-title":"J Clin Pharm Ther"},{"key":"R9-20250819","first-page":"1821","article-title":"Clinical evaluation of sulbactam\/cefoperazone in the pediatric infections.","volume":"37","author":"Meguro","year":"1984","journal-title":"Jpn J Antibiot"},{"key":"R10-20250819","first-page":"1831","article-title":"Fundamental and clinical studies of sulbactam\/cefoperazone in the pediatric field.","volume":"37","author":"Iwata","year":"1984","journal-title":"Jpn J Antibiot"},{"key":"R11-20250819","first-page":"1846","article-title":"Experimental and clinical studies of sulbactam\/cefoperazone in pediatric field.","volume":"37","author":"Nakashima","year":"1984","journal-title":"Jpn J Antibiot"},{"key":"R12-20250819","first-page":"1859","article-title":"Studies on sulbactam\/cefoperazone in the field of pediatrics.","volume":"37","author":"Iwai","year":"1984","journal-title":"Jpn J Antibiot"},{"key":"R13-20250819","first-page":"1880","article-title":"Laboratory and clinical studies of sulbactam\/cefoperazone in the pediatric field.","volume":"37","author":"Nishimura","year":"1984","journal-title":"Jpn J Antibiot"},{"key":"R14-20250819","first-page":"1893","article-title":"Basic and clinical studies of sulbactam\/cefoperazone in pediatric field.","volume":"37","author":"Haruta","year":"1984","journal-title":"Jpn J Antibiot"},{"key":"R15-20250819","first-page":"1898","article-title":"Fundamental and clinical studies of sulbactam\/cefoperazone in the pediatric field.","volume":"37","author":"Motohiro","year":"1984","journal-title":"Jpn J Antibiot"},{"key":"R16-20250819","first-page":"2174","article-title":"Fundamental and clinical studies of sulbactam\/cefoperazone in the field of pediatrics.","volume":"37","author":"Nakazawa","year":"1984","journal-title":"Jpn J Antibiot"},{"key":"R17-20250819","first-page":"2457","article-title":"Basic and clinical evaluation of sulbactam\/cefoperazone in the field of pediatrics.","volume":"37","author":"Toyonaga","year":"1984","journal-title":"Jpn J Antibiot"},{"key":"R18-20250819","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN)\u2014a Perl module for NONMEM related programming.","volume":"75","author":"Lindbom","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"key":"R19-20250819","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1046\/j.1198-743x.2001.00295.x","article-title":"Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters.","volume":"7","author":"Jacobs","year":"2001","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl. 1","key":"R20-20250819","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1086\/344653","article-title":"Prevention of resistance: a goal for dose selection for antimicrobial agents.","volume":"36","author":"Drusano","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R21-20250819"},{"key":"R22-20250819","first-page":"896","article-title":"Effects of sulbactam on the activity of cefoperazone against various clinical isolates.","volume":"42","author":"Uete","year":"1989","journal-title":"Jpn J Antibiot"},{"key":"R23-20250819","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/jac\/dkaa071","article-title":"Developmental population pharmacokinetics-pharmacodynamics and dosing optimization of cefoperazone in children.","volume":"75","author":"Shi","year":"2020","journal-title":"J Antimicrob Chemother"},{"year":"2024","key":"R24-20250819"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004832","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T15:07:34Z","timestamp":1755616054000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004832","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"type":"print","value":"0891-3668"},{"type":"electronic","value":"1532-0987"}],"subject":[],"published":{"date-parts":[[2025,4,11]]}}}